SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
LIVE Programme CEST time
13:50-14:05 Treatment Issues in Older ALL Selina Luger (Philadelphia)
14:05-14:20 Management of Relapsed ALL Elias Jabbour (Houston)
BRIEF ORAL COMMUNICATION:
14:20-14:30 T(1;19)(q23;p13) TCF3-PBX1 May Not be an Intermediate-Risk Jordi Ribera (Badalona)
Subtype in Adult B-Cell Precursor Acute Lymphoblastic
Leukemia Patients Treated with MRD-Oriented Protocols from
the Pethema Group
14:30-15:00 Panel discussion
SESSION V – NEW ADVANCES IN ALL
Chairs: Hervé Dombret (Paris) & Shannon Maude (Philadelphia)
15:00-15:05 Introduction Hervé Dombret & Shannon Maude
15:05-15:20 The Critical Role of Microenvironment in ALL Adele Fielding (London)
15:20-15:35 TKI Use in Ph+/Ph-like Diseases Stephen Hunger (Philadelphia)
15:35-15:50 New ALL Drugs Matthew Wieduwilt (San Diego)
BRIEF ORAL COMMUNICATIONS:
15:50-16:00 Lysosome-Mediated Dysregulation of Lipid Metabolism Ruth M Risueño (Barcelona)
Selectively Induces Autophagy-Dependent Cell Death in T-ALL
16:00-16:10 Pharmacologic Inhibition of DYRK1A Results in Christian Hurtz (Philadelphia)
Hyperphosphorylation of ERK and Consequently in Apoptosis
of KMT2A-Rearranged ALL
16:10-16:20 Oncogenic Cooperation between the TCF7-SPI1 fusion and Quentin Van Thillo (Leuven)
NRAS(G12D) Requires β-Catenin Activity to Drive T-Cell
Acute Lymphoblastic Leukemia.
16:20-16:50 Panel discussion
16:50-17:00 Break
SESSION VI – CAR T-CELLS & ALLOGENEIC HSCT
Chairs: Adele Fielding (London) & Nicolas Boissel (Paris)
17:00-17:05 Introduction Adele Fielding & Nicolas Boissel
17:05-17:20 Outcome of ALL Patients Treated with CAR T-cells Shannon Maude (Philadelphia)
17:20-17:35 New CARs for B-cell Precursor ALL Claire Roddie (London)
17:35-17:50 Post-transplant Interventions David Marks (Bristol)
17:50-18:20 Panel discussion
3